LISTING OF CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

What is claimed is:

1. (Currently amended) A pharmaceutical composition comprising (i) a first specific binding agent selected from an isolated antibody that specifically binds a target toxin or a large binding fragment of an antibody ~~which~~ , wherein the large binding fragment specifically binds ~~a~~ the target toxin, and (ii) a second specific binding agent ~~which~~ that comprises a small binding fragment of an antibody ~~which~~ wherein the small binding fragment binds ~~said~~ the toxin.

2. (Currently amended) The composition of claim 1 wherein the first specific binding agent comprises ~~a~~ the large binding fragment of an antibody.

3. (Previously presented) The composition of claim 2 wherein the large binding fragment of an antibody is an $F(ab')_2$ or $F(ab)_2$ fragment.

4. (Currently amended) The composition of claim 1 wherein the first specific binding agent is ~~an~~ the antibody, which is IgG or IgT.

5. (Previously presented) The composition of claim 4 wherein the antibody is humanised.

6. (Currently amended) The composition of claim 1 wherein the second specific binding agent ~~comprises~~ is selected from the group consisting of an Fab, Fab', a single chain (sc) antibody or an FV, VH or VK fragment.

7. (Currently amended) The composition of claim 6 wherein the second specific binding agent ~~comprises~~ is an Fab or Fab' fragment.

8. (Currently amended) The composition of claim 1 wherein the first and/or second binding agents are ~~derived~~ from polyclonal antibodies.

9. (Currently amended) The composition of claim 1 wherein the first and/or second binding agents are ~~derived~~ from monoclonal antibodies.

10. (Previously presented) The composition of claim 1 wherein at least one of the first or second specific binding agents includes a section corresponding to part of the Fc region of an antibody.

11. (Previously presented) The composition of claim 1 wherein the toxin is a Botulinum toxin.

12. (Previously presented) The composition of claim 11 wherein the first and second specific binding agents bind at least one of type A, B, C, D, E, F or G botulinum toxin.

13. (Previously presented) The composition of claim 12 wherein the composition comprises sets of first and second specific binding agents each set of specific binding agents binding a different one of botulinum toxins A, B, C, D, E, F or G.

14. (Previously presented) The composition of claim 1 wherein the w/w ratio of the first specific binding agent to the second specific binding agent is in the range of from 90:10 to 10:90.

15. (Previously presented) The composition of claim 14 wherein the w/w

ratio of the first specific binding agent to the second specific binding agent is in the range of from 70:30 to 30:70.

16. (Previously presented) The composition of claim 15 wherein the w/w ratio of the first specific binding agent to the second specific binding agent is in the range of from 60:40 to 40:60.

17. (Previously presented) The composition of claim 1 which further comprises a pharmaceutically acceptable carrier or excipient.

18. (Previously presented) The composition of claim 1 which is suitable for oral, parenteral, or intranasal administration, or for administration by inhalation or insufflation.

19. (Withdrawn-Currently amended) A method for treating the adverse effects of a toxin on a mammal comprising administering to a mammal in need thereof a composition comprising (i) a first specific binding agent selected from an isolated antibody that specifically binds a target toxin or a large binding fragment of an antibody ~~which~~ wherein the large binding fragment specifically binds ~~a~~ the target toxin, and (ii) a second specific binding agent ~~which~~ that comprises a small binding fragment of an antibody ~~which~~ wherein the small binding fragment binds ~~said~~ the toxin.

20. (Cancelled)

21. (Withdrawn-Currently amended) A method of preventing the effects of a toxin on a mammal, said method comprising administering to a mammal in need thereof~~,~~ a composition comprising (i) a first specific binding agent selected from an isolated antibody that specifically binds a target toxin or a large binding fragment of an antibody ~~which~~ wherein the large binding fragment specifically binds a target toxin, and (ii) a second specific

binding agent ~~which~~ that comprises a small binding fragment of an antibody ~~which~~ wherein the small binding fragment binds ~~said~~ the toxin.

22. (Cancelled)